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Abstract
Background: The aim of this analysis was to determine the relative influence of disease and non-disease factors on 
areal bone mineral density (BMDa) in a primary care based cohort of women with inflammatory polyarthritis.
Methods: Women aged 16 years and over with recent onset inflammatory polyarthritis were recruited to the Norfolk 
Arthritis Register (NOAR) between 1990 and 1993. Subjects were examined at both baseline and follow up for the 
presence of tender, swollen and deformed joints. At the 10th anniversary visit, a sub-sample of women were invited to 
complete a bone health questionnaire and attend for BMDa (Hologic, QDR 4000). Linear regression was used to 
examine the association between BMDa with both (i) arthritis-related factors assessed at baseline and the 10th 
anniversary visit and (ii) standard risk factors for osteoporosis. Adjustments were made for age.
Results: 108 women, mean age 58.0 years were studied. Older age, decreasing weight and BMI at follow up were all 
associated with lower BMDa at both the spine and femoral neck. None of the lifestyle factors were linked. Indices of 
joint damage including 10th anniversary deformed joint count and erosive joint count were the arthritis-related 
variables linked with a reduction in BMDa at the femoral neck. By contrast, disease activity as determined by the 
number of tender and or swollen joints assessed both at baseline and follow up was not linked with BMDa at either site.
Conclusion: Cumulative disease damage was the strongest predictor of reduced femoral bone density. Other disease 
and lifestyle factors have only a modest influence.
Background
Data from hospital-clinic based studies suggest that
patients with rheumatoid arthritis (RA) have a reduction
in areal bone mineral density (BMDa) at both the hip and
spine compared to non-RA controls [1-4]. Such studies of
patients with established disease will tend to exclude sub-
jects with less marked disease who may be managed in
primary care, either from the outset or discharged from
specialist care early during the disease course. We studied
a sample of women ten years prospectively, recruited fol-
lowing the onset of inflammatory arthritis presenting to
primary care, to determine the relative influence of both
arthritis and non-arthritis related factors on BMDa at the
spine and femoral neck 10 years after disease onset.
Methods
The subjects included in this analysis were recruited to
the Norfolk Arthritis Register (NOAR) between 1990 &
1993, a primary care based inception cohort of adults
with early inflammatory arthritis [5]. At baseline, subjects
were examined by a trained research nurse for the pres-
ence of tender, swollen and deformed joints and had
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Page 2 of 6blood taken for c-reactive protein (CRP) and rheumatoid
factor measurement. They also completed the Health
Assessment Questionnaire (HAQ) [6]. Subjects are fol-
lowed prospectively including assessments at 5, 7 and 10
years. Radiographs of the hands were performed at 5
years on all subjects who consented, and then again at 10
years if erosive change was present on the 5 year radio-
graph. Radiographs were assessed according to the
method of Larsen [7] by two independent observers.
Overall scores were compared between the observers and
if the scores differed by more than 10%, the films were re-
examined by both observers jointly. A third person adju-
dicated if there was disagreement. A Larsen score of two
or more for an individual joint indicated the presence of
erosive change. Subjects are asked additionally at these
visits about use of steroids and disease modifying anti-
rheumatic drugs (DMARD's). NOAR subjects continue
to attend for their 10th anniversary assessment. A subset
(108) of those who were among the first to attend agreed
to take part in a bone health survey which comprised an
interviewer administered questionnaire and bone densi-
tometry at the spine and femoral neck. The questionnaire
was derived from a previously validated questionnaire on
osteoporosis lifestyle risk factors [8] and included ques-
tions concerning:
(i) level of physical activity undertaken at work or
home during three periods of adult life: 15-25 years,
25-50 years and 50 years and over (response set =
light/moderate/heavy/very heavy)
(ii) time spent walking or on a bicycle out of doors
each day (response set = none/< 30 minutes/30 min-
utes to 1 hour/> 1 hour)
(iii) if ever smoked, the number of cigarettes smoked
a day
(iv) alcohol consumption in the previous year
(response set = every day/5-6 days per week/3-4 days
per week/1-2 days per week/less than once a week/
not at all).
It also included questions about age at menarche and
menopause and use of both the oral contraceptive pill and
hormone replacement therapy. The revised questionnaire
was not formally validated. Height and weight were mea-
sured using standard equipment and body mass index
(BMI) calculated. Bone densitometry (Hologic, QDR
4000) was performed at the spine and femoral neck sites.
All aspects of the study were in compliance with the Hel-
sinki Declaration and approved by the Norfolk Research
Ethics Committee.
Analysis
Linear regression was used to determine the association
between bone mineral density (BMDa) at the spine and
hip and the various arthritis and non-arthritis related fac-
tors with BMDa as the dependent variable and adjust-
ments made for age. We looked at the association
between arthritis related factors assessed at baseline and
BMDa, and arthritis related factors assessed at 10 years
and BMDa. We looked also at cumulative disease activity
by combining clinical data available from the preceding
assessment periods (baseline, 5, 7 and 10 years) and cate-
gorising these into tertiles. For CRP we categorised the
number of times individuals had an elevated CRP level
(assessed at baseline, 5 and 10 years). The results are
expressed as β coefficients and 95% confidence intervals
(CI). Statistical analysis was performed using STATA ver-
sion 9.2 (StataCorp, 2007).
Results
Subject characteristics
A total of 108 women (mean age 58.0 years, standard
deviation [SD] = 13.2) were included in the analysis.
Mean height was 1.6 m, weight 57.5 Kg and body mass
index 21.6 Kg/m2. Mean age at menarche was 12.8 years.
Of the 38 women who had reached natural menopause,
the mean age at menopause was 48.0 years. Mean BMDa
was 0.76 g/cm2 (SD = 0.11) at the femoral neck and 0.96
g/cm2 (SD = 0.14) at the lumbar spine respectively. Fifty
three percent of subjects reported walking or cycling for
1/2 an hour or more daily, while 47%, 61% and 49% of
subjects reported undertaking heavy or very heavy physi-
cal activity between the ages of 15-25, 25-50 and 50 years
and over respectively. Fifty one percent of subjects
reported ever having smoked, while 23% reported con-
suming alcohol on more than one day per week. Sixty
percent reported taking the oral contraceptive pill in the
past and 39% were currently taking hormone replace-
ment therapy (HRT). The median (interquartile range)
swollen and tender joint counts at baseline were 7 (3-15)
and 9 (4-19) and at 10 years were 2 (0-6) and 2 (0-8)
respectively. The median (interquartile range) deformed
joint count at 10 years was 2 (0-7). Mean CRP level at
baseline and 10 years was 14.1 and 12.3 mg/L respec-
tively. 71 (66%) subjects satisfied the American College of
Rheumatology (ACR) tree criteria at baseline and 86
(80%) at 10 years. Forty eight percent of subjects reported
having ever taken DMARDs and 18% reported having
taken steroids during follow up. Of those who had hand
radiographs performed at the 10th anniversary visit (n =
36) the median (interquartile range) number of erosive
joints was 6 (3-14).
Determinants of BMDa
As expected BMDa decreased with age (per year) at both
the femoral neck (β coeff = -0.003; 95%CI -0.005, -0.002)
and lumbar spine (β coeff = -0.004; 95%CI -0.006, -0.002).
The influence of non-arthritis related factors on BMDa
are presented in Table 1. Increasing weight (per 10 kg)
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oral neck (β coeff = 0.030;95%CI 0.004, 0.056) and lumbar
spine (β coeff = 0.034;95%CI 0.002, 0.066). Similarly, BMI
was associated with a significant increase in BMDa at
both measurement sites. By contrast there was no associ-
ation between physical activity, either lifetime or current,
as determined by walking or cycling daily, with BMDa at
either the femoral neck or spine. Similarly there was no
association between BMDa and smoking or alcohol con-
sumption. Increasing age at menarche (per year) was
associated with a reduction in BMDa at both the femoral
neck (β coeff = -0.017; 95%CI -0.032, -0.002) and lumbar
spine (β coeff = -0.018; 95%CI -0.036, -0.001). Age at nat-
ural menopause, use of the oral contraceptive pill and
HRT did not appear to be linked with BMDa at either site.
The influence of arthritis-related factors assessed at
both baseline and 10 years on BMDa are shown in Table 2.
Disease activity expressed as active (swollen, tender or
both) counts assessed either at baseline or at the 10th
anniversary visit showed no association with BMDa.
Those with a CRP greater than 10 either at baseline or
follow up had higher BMDa (at the 10th anniversary) at
both the spine and femoral neck though the confidence
intervals embraced unity. Cumulative disease activity
(swollen, tender joint counts) were not linked with BMDa
(data not shown). For CRP, compared to those with CRP
levels < 10 throughout, those who had elevated levels on
one, or two or more occasions had higher BMDa at the
femoral neck (p < 0.05). DMARD use and steroid therapy
(both ever and also when expressed as duration of time
on therapy), were not linked with BMDa at either site.
Rheumatoid factor assessed either at baseline or 10 years
was unrelated to BMDa. Disability as measured using
HAQ was not linked with BMDa. Not all the subjects in
this cohort satisfied ACR tree criteria for RA, either at
baseline or by the 10th anniversary. However stratification
by 'RA' status also showed no association with BMDa. By
contrast measures of structural damage were linked.
Thus increased deformed joint count, as a measure of
cumulative joint damage was linked with a reduction in
BMDa at both sites. The effect was large, equivalent to
approximately a 0.5 SD reduction for those above the
lowest tertile of joint count and this was significant at the
femoral neck. In the sub-sample of women with hand
radiographs available those in both the mid and upper
tertile of erosive joint count had lower BMDa at both the
hip and spine than those in the lower tertile though the
result was significant for those in the middle tertile only.
Discussion
In this inception cohort of women presenting to primary
care with inflammatory polyarthritis there were several
interesting findings relating to BMDa assessed after 10
years. Standard osteoporosis risk factors apart from age
and body mass had relatively little impact. Of the disease
factors considered those relating to activity and disability
were not predictive of bone loss, whereas measures of
Table 1: Influence of anthropometric, hormonal and lifestyle factors on BMDa at the spine and femoral neck.
Femoral Neck (g/cm2) Lumbar Spine (g/cm2)
β1 coefficient β1 coefficient
Height (per 10 cm) -0.014 (-0.047, 0.019) 0.001 (-0.040, 0.042)
Weight (per 10 kg) 0.030 (0.004, 0.056)* 0.034 (0.002, 0.066)*
BMI (kg/m2) 0.008 (0.002, 0.014)* 0.008 (0.001, 0.016)*
Menarche (years) -0.017 (-0.032, -0.002)* -0.018 (-0.036, -0.001)*
Age at natural menopause (years) 0.001 (-0.004, 0.005) 0.005 (-0.001, 0.010)
Oral contraceptive pill use: yes vs no 0.005 (-0.051, 0.060) -0.002 (-0.069, 0.065)
Hormone replacement therapy: yes vs no 0.027 (-0.023, 0.077) 0.036 (-0.027, 0.100)
Walking or cycling: >= 1/2 hr vs < 1/2 hr 0.040 (-0.005, 0.085) -0.005 (-0.059, 0.050)
Activity aged 15-25 yrs: heavy/very heavy vs light/moderate 0.036 (-0.008, 0.080) 0.031 (-0.021, 0.084)
Activity aged 25-50 yrs: heavy/very heavy vs light/moderate 0.021 (-0.026, 0.068) 0.001 (-0.057, 0.058)
Activity aged 50 yrs and over: heavy/very heavy vs light/moderate -0.023 (-0.078, 0.033) -0.055 (-0.122, 0.012)
Ever smoked: yes vs no 0.023 (-0.021, 0.066) -0.008 (-0.059, 0.042)
Alcohol: >= 1 dy/wk vs < 1 dy/wk 0.032 (-0.019, 0.083) -0.001 (-0.062, 0.061)
1adjusted for age.
*p < 0.05
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Page 4 of 6joint damage were strongly predictive, especially at the
femoral neck.
There are several limitations which need to be consid-
ered in interpreting the results. The subjects were delib-
erately selected to include all cases of inflammatory
polyarthritis and not restrict inclusion to those with RA.
Indeed we have shown that assigning criteria for RA is
unstable in this setting during the first 5 years of disease
[9]. As shown above however the results are stable inde-
pendent of RA status. In this study we looked at BMDa in
a subset of subjects attending their 10th anniversary visit.
It is possible that those who had BMDa performed may
have differed from those who did not. However, those
scanned did not differ in terms of joint count (swollen
joint count mean = 3.9 vs 3.1; p = 0.11), HAQ score (mean
= 1.02 vs 1.04; p = 0.82), or CRP level (mean = 12.3 mg/L
vs 13.3; p = 0.59), from those who did not providing some
reassurance against selection bias though we can not
exclude this. Hand radiographs at the 10th anniversary
were only available on a proportion of the subjects. In
order to have a 10th anniversary radiograph, erosive
change had to be present on the 5th anniversary radio-
graph, so it is likely that these subjects had more severe
disease. Indeed we found these subjects to be slightly











Lower Referent Referent Referent Referent
Mid -0.043 (-0.096, 0.009) 0.003 (-0.061, 0.066) -0.015 (-0.068, 0.039) -0.061 (-0.123, 0.001)
Upper -0.024 (-0.073, 0.025) -0.012 (-0.071, 0.048) -0.018 (-0.071, 0.035) -0.020 (-0.081, 0.040)
Tender joint count:
Lower Referent Referent Referent Referent
Mid 0.001 (-0.051, 0.052) -0.020 (-0.081, 0.042) -0.025 (-0.075, 0.026) -0.015 (-0.075, 0.045)
Upper -0.023 (-0.076, 0.029) -0.027 (-0.090, 0.036) 0.004 (-0.051, 0.058) -0.007 (-0.070, 0.057)
Both swollen & tender 
jt count:
Lower Referent Referent Referent Referent
Mid 0.022 (-0.030, 0.074) -0.007 (-0.070, 0.056) -0.012 (-0.078, 0.055) 0.020 (-0.059, 0.098)
Upper -0.009 (-0.059, 0.040) 0.002 (-0.058, 0.061) -0.001 (-0.051, 0.048) 0.008 (-0.050, 0.066)
Deformed joint count:
Lower - - Referent Referent
Mid -0.047 (-0.098, 0.004) -0.059 (-0.121, 0.003)
Upper -0.067 (-0.117, -0.018)* -0.046 (-0.106, 0.015)
Erosive joint count:
Lower - - Referent Referent
Mid -0.084 (-0.160, -0.008)* -0.126 (-0.213, -0.039)*
Upper - - -0.031 (-0.100, 0.039) -0.014 (-0.093, 0.066)
CRP level:
Normal <10 mg/L Referent Referent Referent Referent
Elevated ≥10 mg/L 0.044 (-0.003, 0.091) 0.041 (-0.017, 0.100) 0.031 (-0.013, 0.075) 0.030 (-0.026, 0.086)
HAQ score (0-3) -0.004 (-0.034, 0.027) -0.003 (-0.040, 0.034) -0.003 (-0.031, 0.025) -0.010 (-0.043, 0.024)
Steroid use (ever vs 
never)
- - 0.006 (-0.055, 0.067) 0.008 (-0.065, 0.081)
DMARD use (ever vs 
never)
- - 0.016 (-0.035, 0.068) -0.016 (-0.079, 0.048)
1adjusted for age. *p < 0.05
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Page 5 of 6older, have more joint involvement, higher CRP levels
and HAQ score compared to those who did not have a
10th anniversary hand radiograph. We did not have data
on current smoking or OCP use at the time of bone den-
sity assessment or during the 10 year period of the study,
so the influence of these could not be assessed. Finally the
sample size was relatively small and the study had limited
power to detect weak associations.
The lack of influence of disease activity on bone loss
might be explained by measurement imprecision in rela-
tion to the joint counts. In an attempt to minimise this all
of the assessments were undertaken by trained research
nurses; annual comparative assessments were conducted
to ensure standardisation of assessment. Four patients
(with active joints) were invited to take part in the assess-
ment process. Each nurse assessed each patient together
with an independent observer. The results were com-
pared, discrepancies discussed and repeat examinations
performed as necessary to ensure agreement. Further any
such imprecision should have applied equally to
deformed joint counts which are perhaps harder to stan-
dardise, yet which showed a strong influence on BMDa.
Data from some though not all studies of patients with
RA have suggested an association between disease activ-
ity assessed using erythrocyte sedimentation rate (ESR)
or CRP and reduced bone mass [4,10,11]. In our long
term follow up study, we observed a trend towards a pos-
itive association between CRP and bone mass, though the
association did not attain statistical significance. This
positive association has been reported previously though
the mechanism is unclear [4].
In contrast to some though not all studies [2,10,12-15],
we found no influence of corticosteroid use. We looked,
however, only at ever use of steroids during the follow up
period. There was insufficient information about dose of
steroids used during the follow up period to allow assess-
ment of the impact of current or cumulative dose in the
study.
Previous studies have shown an inverse association
with joint damage in RA as expressed by the Larsen score
and BMDa by dual energy x-ray absorptiometry (DXA)
[16-18]. In our study disease damage as determined both
by the deformed joint count and erosive joint count at fol-
low up was linked with increased bone loss. Such mea-
sures presumably represent a better marker of cumulative
disease activity resulting over a long period in joint dam-
age - though additional factors including immobility
related bone loss may also be a factor. Many of the life-
style factors investigated, such as smoking, exercise and
hormonal use, had no significant influence on BMDa in
this group. It is possible that associations with these vari-
ables were masked given the presence of longstanding
arthritis. As expected based on studies of women without
inflammatory arthritis, increasing age at menarche,
weight and body mass index were linked with increased
BMDa [19-21].
Conclusions
In summary, in this group of women with longstanding
inflammatory polyarthritis, cumulative disease damage
was the strongest predictor of reduced bone density.
Other disease and lifestyle factors had only a modest
influence.
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